New clinical research presented at the ENDO 2026 annual meeting suggests that glucagon-like peptide-1 (GLP-1) receptor agonists may offer a dual benefit for men, significantly improving both testosterone levels and sperm quality in those suffering from obesity-related hypogonadism. The study, led by Pratibha Natesh, MBBS, MRCP, MRes, an endocrinologist at University Hospitals Coventry and Warwickshire and Warwick Medical School in the United Kingdom, highlights a potential paradigm shift in how physicians approach male reproductive health. By targeting the underlying metabolic dysfunction associated with excess weight, these medications appear to restore natural hormonal balance more effectively than traditional hormone replacement therapies in certain populations.
The research team conducted a comprehensive systematic review and meta-analysis of existing medical literature to determine the extent of these benefits. After filtering through global medical databases for randomized controlled trials (RCTs), the researchers focused on studies comparing GLP-1 analogs against placebos or alternative treatments in men aged 18 to 65. The primary objective was to evaluate changes in the reproductive axis—specifically testosterone levels and the hormones that regulate testicular function—while also monitoring secondary indicators such as sperm morphology, body mass index (BMI), glycemic control, and lipid profiles.
Methodology and the Scope of the Meta-Analysis
The investigation conducted by the University Hospitals Coventry and Warwickshire team was designed to minimize bias and ensure the highest level of clinical relevance. Two independent reviewers meticulously screened the available literature, ultimately identifying five high-quality clinical trials that met the strict eligibility criteria. These trials provided a robust dataset covering various GLP-1 formulations, including semaglutide and liraglutide, and tracked patient outcomes over periods ranging from 16 to 24 weeks.
A critical component of the study was the assessment of the hypothalamic-pituitary-gonadal (HPG) axis. In men with obesity, this axis is often suppressed. Excess adipose tissue (body fat) contains high levels of the enzyme aromatase, which converts testosterone into estrogen. This hormonal imbalance signals the brain to reduce the production of luteinizing hormone (LH) and follicle-stimulating hormone (FSH), leading to lower natural testosterone production and impaired sperm development. The researchers sought to determine if GLP-1 medications could break this cycle by improving metabolic health and reducing fat mass.
Clinical Findings: Semaglutide and Liraglutide Results
The data extracted from the five clinical trials yielded promising results regarding the safety and efficacy of GLP-1s in a reproductive context. Contrary to concerns that rapid weight loss might negatively impact nutritional status and, by extension, fertility, the scientific reports indicated that GLP-1s have no detrimental effects on male hormones, sexual function, or sperm quality. In fact, the opposite was often observed.
One specific 24-week study involving semaglutide revealed notable improvements in sperm morphology—the size and shape of sperm, which is a key predictor of fertility. Additionally, patients in this trial saw a stabilization of hormone levels alongside improved cholesterol profiles, suggesting a holistic improvement in cardiovascular and reproductive health.
In another significant trial lasting 16 weeks, researchers focused on the use of liraglutide in men who were diagnosed with both obesity and low testosterone. The results were striking: the participants experienced substantial increases in serum testosterone and related gonadotropins. Most notably, the study found that the overall health outcomes for these men were superior to those typically observed with testosterone replacement therapy (TRT) alone. While TRT can increase circulating testosterone, it often suppresses the natural production of FSH and LH, which can lead to testicular shrinkage and infertility. Liraglutide, by contrast, appeared to support the body’s natural production mechanisms.
A Shift in the Treatment Paradigm for Male Hypogonadism
The implications of this research are significant for the field of endocrinology. For decades, the standard of care for men with low testosterone (hypogonadism) has been the direct administration of exogenous testosterone. However, as Dr. Pratibha Natesh noted during her presentation, this approach often addresses the symptom rather than the cause, particularly in patients whose hormonal issues stem from obesity.
"This work supports a shift away from prescribing testosterone replacement in men with obesity and low testosterone and toward treating the underlying cause—excess weight and poor metabolic health—which can naturally restore hormone levels and preserve fertility," Natesh stated.
By utilizing GLP-1s, clinicians can facilitate significant weight loss and improve insulin sensitivity. As the patient’s metabolic profile improves, the suppressive effect of excess fat on the HPG axis is lifted. This allows the pituitary gland to resume normal signaling to the testes, potentially restoring fertility in men who might otherwise have been rendered infertile by standard TRT. This "metabolic restoration" approach is increasingly favored in modern medicine, where the goal is to achieve homeostasis rather than relying on lifelong supplementation.
Chronology of GLP-1 Development and Reproductive Research
The journey of GLP-1 medications from diabetes treatments to potential fertility aids has been a rapid evolution in the 21st century:
- 2005: The FDA approves the first GLP-1 receptor agonist, exenatide, primarily for the treatment of Type 2 diabetes.
- 2014: Liraglutide (Saxenda) receives approval for chronic weight management, marking the beginning of the "weight loss revolution" in endocrinology.
- 2017-2021: The approval of semaglutide (Ozempic and Wegovy) brings GLP-1s into the cultural mainstream, showing unprecedented efficacy in weight reduction.
- 2022-2024: Anecdotal reports and small-scale observational studies begin to suggest that men on these medications are experiencing improved libido and higher partner pregnancy rates.
- 2026: The presentation by Dr. Natesh at ENDO 2026 provides a formalized meta-analysis that validates these observations through controlled clinical data.
This timeline reflects a growing understanding that metabolic health is the cornerstone of reproductive health. As obesity rates continue to rise globally, the intersection of these two fields has become a priority for medical researchers.
Supporting Data: Obesity and the Male Fertility Crisis
The relevance of the ENDO 2026 study is underscored by current global health statistics. According to the World Health Organization (WHO), obesity rates have nearly tripled since 1975. Simultaneously, data from various longitudinal studies suggest a decline in average sperm counts and testosterone levels in men over the last several decades.
Research indicates that a BMI over 30 is associated with a significantly higher risk of oligozoospermia (low sperm count) and azoospermia (absence of sperm). Furthermore, for every 10kg (22 lbs) of weight a man loses, there is a measurable increase in testosterone levels. The data provided by the GLP-1 trials suggests that the weight loss achieved via these medications is particularly effective at targeting visceral fat, which is the most metabolically active and hormonally disruptive type of fat.
Broader Implications and Future Clinical Outlook
While the findings are overwhelmingly positive, the research team maintained a cautious tone regarding the immediate widespread adoption of GLP-1s as a primary treatment for infertility. Dr. Natesh emphasized that the number of studies currently available is relatively small and that the results can vary based on the specific medication used and the baseline health of the patient.
"This research is important because it helps to determine whether the improvement in the reproductive hormones is driven solely by weight loss or whether the GLP-1 analogs have a direct impact on the reproductive axis itself," Natesh explained.
Currently, GLP-1 medications are not FDA-approved or indicated for the treatment of male infertility or hypogonadism. Most of the reproductive benefits observed are considered indirect—a secondary effect of the massive metabolic improvements and weight reduction the drugs facilitate. However, the potential for these drugs to become a staple in fertility clinics is high, especially for men who are not candidates for TRT due to a desire for future paternity.
The medical community is now calling for larger, multi-center, long-term randomized controlled trials. Future research will likely focus on whether GLP-1s can be combined with other fertility treatments or if they should be used as a "pre-treatment" to optimize a man’s metabolic state before attempting conception, either naturally or via assisted reproductive technologies (ART).
Conclusion: A New Frontier in Patient Care
The research presented at ENDO 2026 represents a critical step forward in understanding the far-reaching effects of GLP-1 medications. Beyond weight loss and blood sugar management, these drugs appear to hold the key to unlocking better reproductive outcomes for millions of men. By providing evidence-based information, Dr. Natesh and her team hope to empower both patients and healthcare providers to look beyond the scale and consider the holistic benefits of metabolic health.
"Improving metabolic health can have positive effects far beyond weight alone," Natesh concluded. "This research has the potential to improve both metabolic and reproductive health outcomes, making it highly relevant to the future of endocrinology and patient care."
As the pharmaceutical landscape continues to evolve, the integration of metabolic management into reproductive medicine marks a significant milestone. For men struggling with the dual burden of obesity and low testosterone, the emergence of GLP-1s as a viable pathway to hormonal restoration offers a new sense of hope for both their general well-being and their dreams of fatherhood.
